# Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)

> **NCT01953536** · PHASE2 · WITHDRAWN · sponsor: **Endocyte**

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Vintafolide 2.5 mg
- **DRUG:** Paclitaxel 80 mg/m^2
- **DRUG:** Etarfolatide
- **DRUG:** Folic acid
- **DRUG:** Premedication for Paclitaxel

## Key facts

- **NCT ID:** NCT01953536
- **Lead sponsor:** Endocyte
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-04
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01953536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01953536, "Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01953536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*